This HTML5 document contains 36 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n13http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00002/identifier/genbank/
foafhttp://xmlns.com/foaf/0.1/
n23http://linked.opendata.cz/resource/drugbank/company/
n5http://linked.opendata.cz/resource/mesh/concept/
n9http://linked.opendata.cz/resource/drugbank/dosage/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00002/identifier/wikipedia/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00002/identifier/pharmgkb/
n22http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n17http://linked.opendata.cz/resource/drugbank/patent/
n15http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00002/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n16http://www.drugs.com/cdi/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00002/identifier/national-drug-code-directory/
n8http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n20http://linked.opendata.cz/resource/atc/
n19http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00002
rdf:type
n3:Drug
n3:description
Epidermal growth factor receptor binding FAB. Cetuximab is composed of the Fv (variable; antigen-binding) regions of the 225 murine EGFr monoclonal antibody specific for the N-terminal portion of human EGFr with human IgG1 heavy and kappa light chain constant (framework) regions.
n3:dosage
n9:271B3E7F-363D-11E5-9242-09173F13E4C5 n9:271B3E80-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
114 hrs
n3:indication
For treatment of EGFR-expressing metastatic colorectal cancer in patients who are refractory to other irinotecan-based chemotherapy regimens. Cetuximab is also indicated for treatment of squamous cell carcinoma of the head and neck in conjucntion with radiation therapy.
owl:sameAs
n15:DB00002 n22:DB00002
dcterms:title
Cetuximab
adms:identifier
n7:PA10040 n10:J00228 n11:66733-948-23 n21:DB00002 n24:Cetuximab
n3:mechanismOfAction
Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.
n3:packager
n23:271B3E7D-363D-11E5-9242-09173F13E4C5 n23:271B3E7E-363D-11E5-9242-09173F13E4C5 n23:271B3E7B-363D-11E5-9242-09173F13E4C5 n23:271B3E7C-363D-11E5-9242-09173F13E4C5
n3:patent
n17:1340417
n3:synonym
Anti EGFR IMC-C225
n3:toxicity
Single doses of cetuximab higher than 500 mg/m<sup>2</sup> have not been tested. There is no experience with overdosage in human clinical trials.
n4:hasConcept
n5:M0422675
foaf:page
n13:erbitux.htm n16:cetuximab.html
n3:Molecular-Formula
n8:271B3E85-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n8:271B3E84-363D-11E5-9242-09173F13E4C5
n19:hasATCCode
n20:L01XC06
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
205923-56-4
n3:category
n3:Hydrophobicity
n8:271B3E82-363D-11E5-9242-09173F13E4C5
n3:Isoelectric-Point
n8:271B3E83-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n8:271B3E81-363D-11E5-9242-09173F13E4C5